FileToto: The Bristol Myers Squibb Research and Development Center in Cambridge Crossing in Cambridge, Massachusetts, on December 27, 2023.
Adam Glanzman | Bloomberg | Getty pictures
Bristol Myers Squibb On Thursday, estimates defeated in the first quarter and increased his sales and profit guidelines for the year because the drug manufacturer lowers the costs.
The company now expects that 2025 revenue between $ 45.8 billion and $ 46.8 billion will be increased, which increases an earlier outlook of around $ 45.5 billion. Bristol Myers also projects the total annual profit of $ 6.70 to 7 per share, which is compared with its previous forecast from USD 6.85 per share.
Remarkably, the company indicated that its guidelines include the estimated effects of current tariffs on US products that were delivered to China. China is a critical market for Bristol Myers. The company previously described its “China 2030 strategy”, which is a plan to bring more medication into the nation in order to satisfy the non -fulfilled medical needs in areas such as stomach cancer and to include more Chinese patients in clinical studies.
But the new prospects do not explain any of President Donald Trump's planned tariffs for pharmaceuticals imported in the USA, said Bristol Myers.
In a profit connection on Thursday, the CEO of Bristol Myers Squibb, Christopher Boerner, said that the company estimated the efforts of the Trump government to increase the US production, but found that it “had to be done in a very thoughtful and conscious way in the pharmaceutical sector”.
He added that it was “just too early to deliver the company's expectations of the company's pharmaceutical-specific tariffs. Nevertheless, Bristol Myers continues” reduction efforts “in order to reduce the risks of a disorder of the supply chain and the lack of Boerner.
“We have an enormous amount of flexibility to move our production if potential tariffs can appear,” said the company's CFO -David Elkins when calling. He added that Bristol Myers has a broad global production network that includes a significant presence in the United States
Bristol Myers said that the increase in Outlook reflects the strength in its portfolio of newer drug brands and the sale of better than expected sales from the legacy portfolio of older medication.
The results come when Bristol Myers collect the expenditure of 2 billion US dollars by the end of 2027, which corresponds to the cost reductions planned to 1.5 billion US dollars by the end of this year.
There is only a few days after Bristol Myers' recently approved schizophrenia medicines, Cobenfy, disappointed in a large clinical study, which caused some Wall Street analysts to significantly reduce their sales forecast for the treatment of several billion dollars.
The company is committed to Cobenfy and other so-called growth portfolio medication in order to compensate for the loss of sales through the best-selling treatments that are supposed to lose exclusivity on the market, including the blockbuster blood thinner Eliquis and the OPDIVO cancer.
Boerner said: “There is a lot of uncertainty as to whether tariffs, a potential economic downturn or restructuring at the FDA and HHS.” He refers to the efforts of the Trump administration, the food and drug authority and other federal health authorities to revise as part of the Ministry of Health and Human Services.
However, the company is still confident that it can “deliver to our patients, employees and shareholders,” he said.
Here is what Bristol Myers reported in the first quarter compared to what Wall Street expected, based on a survey of LSEG analysts:
- Win each share: $ 1.80 adapted compared to USD 1.49
- Revenue: 11.2 billion US dollars expected compared to $ 10.7 billion
Bristol Myers achieved a net profit of 2.5 billion US dollars or $ 1.20 per share in the first quarter. This is compared to a net loss of $ 11.9 billion or a loss of $ 5.89 per share for the period of previous year.
Without certain items, it reported an adjusted result per share of USD 1.80 for the quarter.
The sales of the pharmaceutically fell 6% to 11.2 billion US dollars compared to the same period in the previous year.
Eliquis booked the sales of $ 3.57 billion for the quarter, which decreased by 4% last year. This is above the analysts of 3.34 billion US dollars expected by the analysts, as created by StreetCcount.
More CNBC health insurance
The blood thinner, which Bristol Myers shares with Pfizer, will probably lose market excessiveness by 2028.
The sale of Eliquis could also score in 2026 if a new negotiated price for the drug for certain Medicare patients comes into force after negotiations with the Federal Government. These price talks are an important determination of the inflation reduction law.
The second round of negotiations aims at 15 additional medication and sets new prices that come into force in 2028. This includes the Bristol Myers medication Pomalyyst, which is used to treat blood cancer, which is called multiple myeloma, and another cancer that develops in people with HIV.
The pomalyyst brought 658 million US dollars for the period, which decreased 24% compared to the previous year. Revlimid, a medication for the treatment of adults with a multiple myeloma, decreased in sales of 936 million US dollars in the first quarter, which decreased by 44% compared to the same period last year.
Sales from the company's so-called growth portfolio was $ 5.56 billion in the first quarter, which increased an increase of 16% compared to the same period in the previous year.
OPDIVO generated sales of $ 2.27 billion in the first quarter and rose by 9% compared to the same period last year. This is above the estimation of the analysts of 2.16 billion US dollars for the quarter, said StreetCcount.
In the meantime, Cobenfy booked 27 million US dollars for the first quarter.
